A detailed history of Boothbay Fund Management, LLC transactions in Infla Rx N.V. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 158,035 shares of IFRX stock, worth $353,998. This represents 0.01% of its overall portfolio holdings.

Number of Shares
158,035
Previous 158,035 -0.0%
Holding current value
$353,998
Previous $274,000 12.04%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.47 - $2.03 $24,083 - $33,257
16,383 Added 11.57%
158,035 $243,000
Q3 2023

Nov 14, 2023

BUY
$2.66 - $4.33 $376,794 - $613,353
141,652 New
141,652 $422,000
Q2 2022

Aug 15, 2022

SELL
$0.78 - $1.9 $25,918 - $63,135
-33,229 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$2.35 - $5.58 $70,763 - $168,024
-30,112 Reduced 47.54%
33,229 $158,000
Q3 2021

Nov 15, 2021

SELL
$2.25 - $3.03 $48,507 - $65,323
-21,559 Reduced 25.39%
63,341 $164,000
Q2 2021

Aug 16, 2021

SELL
$2.72 - $4.04 $11,486 - $17,060
-4,223 Reduced 4.74%
84,900 $252,000
Q1 2021

May 17, 2021

BUY
$3.62 - $6.34 $232,237 - $406,736
64,154 Added 256.93%
89,123 $348,000
Q3 2020

Nov 16, 2020

SELL
$3.7 - $5.47 $1,757 - $2,598
-475 Reduced 1.87%
24,969 $106,000
Q2 2020

Aug 14, 2020

SELL
$4.59 - $8.96 $84,176 - $164,317
-18,339 Reduced 41.89%
25,444 $117,000
Q1 2020

May 15, 2020

SELL
$2.65 - $6.08 $43,123 - $98,939
-16,273 Reduced 27.1%
43,783 $167,000
Q4 2019

Feb 14, 2020

SELL
$2.2 - $4.54 $207,792 - $428,807
-94,451 Reduced 61.13%
60,056 $238,000
Q3 2019

Nov 14, 2019

BUY
$2.47 - $3.51 $206,183 - $292,997
83,475 Added 117.52%
154,507 $382,000
Q2 2019

Aug 14, 2019

BUY
$3.06 - $51.61 $217,357 - $3.67 Million
71,032 New
71,032 $224,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $99M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.